Those patients, who had ERα-positive breast tumors with low expression of Nrf2, ABCC1, ABCC3 and NQO1 at the time diagnosis, had a better prognosis after tamoxifen treatment than those patients that were high expressers, with an HR value as high as 4.2. The gene discussed is NFE2L2; the disease is breast neoplasm.